Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all synonyms
Chicken Polyclonal PDE5A Primary Antibody for CM, ICC - ABIN2747175
Uckert, Oelke, Waldkirch, Stief, Albrecht, Tröger, Jonas, Andersson, Hedlund: Cyclic adenosine monophosphate and cyclic guanosine monophosphate-phosphodiesterase isoenzymes in human vagina: relation to nitric oxide synthase isoforms and vasoactive intestinal polypeptide-containing nerves. in Urology 2005
Show all 16 Pubmed References
Cow (Bovine) Polyclonal PDE5A Primary Antibody for ICC, IP - ABIN2750986
Monfort, Muñoz, Felipo: Chronic hyperammonemia in vivo impairs long-term potentiation in hippocampus by altering activation of cyclic GMP-dependent-protein kinase and of phosphodiesterase 5. in Journal of neurochemistry 2005
Show all 4 Pubmed References
Human Polyclonal PDE5A Primary Antibody for ELISA - ABIN563734
Meyer, Sevko, Ramacher, Bazhin, Falk, Osen, Borrello, Kato, Schadendorf, Baniyash, Umansky: Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. in Proceedings of the National Academy of Sciences of the United States of America 2011
Human Monoclonal PDE5A Primary Antibody for IF, ELISA - ABIN563735
Maharaj, OToole, Lynch, Carney, Jarman, Higgins, Morrison, Laffey: Effects and mechanisms of action of sildenafil citrate in human chorionic arteries. in Reproductive biology and endocrinology : RB&E 2009
Human Polyclonal PDE5A Primary Antibody for ELISA, WB - ABIN268768
Morelli, Filippi, Mancina, Luconi, Vignozzi, Marini, Orlando, Vannelli, Aversa, Natali, Forti, Giorgi, Jannini, Ledda, Maggi: Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. in Endocrinology 2004
Cow (Bovine) Polyclonal PDE5A Primary Antibody for IHC, WB - ABIN2789423
Ioki, Wu, Takayama, Motohashi, Wakai, Funahashi: A phosphodiesterase type-5 inhibitor, sildenafil, induces sperm capacitation and penetration into porcine oocytes in a chemically defined medium. in Theriogenology 2016
Thsese findings provide insight into the existence of distinct "pools" of PDE5A in human arterial smooth muscle cells and support the idea that these discrete compartments regulate distinct cGMP-dependent events.
The analogues showed a relative narrow range of Ki values for PDE5A inhibition (1.2-14 nm).
Data indicate that high type 5 phosphodiesterase (PDE5) expression in glioblastoma multiforme (GBM) cells significantly correlated with longer overall survival of patients.
the relationship between PDE5A polymorphisms, diabetes, and the efficacy of sildenafil treatment.The response to sildenafil treatment depends on polymorphisms in the PDE5A gene and the glycemic status of the patients.
Study showed that past attempts to quantify PDE5 mRNA were flawed due to the use of incorrect primers, and that when correct primers are used, PDE5 mRNA is detectable in human brain tissue; that PDE5 protein exists in human brain by western blot and ELISA; and performed immunohistochemistry and demonstrate that PDE5 is present in human neurons.
Our data showed a significant and previously undocumented upregulation of PDE5 in both rat and human BPH (show GLI3 Antibodies).
Overexpression of PDE5 in papillary thyroid carcinomas.
cGMP PDE (show ALDH7A1 Antibodies) isozymes, PDE5 and 10, are elevated in colon tumor cells compared with normal colonocytes, and inhibitors and siRNAs can selectively suppress colon tumor cell growth
Results show that Ser102 and Ser104 may influence the conformational flexibility of PDE5A, which may in turn influence phosphorylation status, allosteric regulation by cGMP or other as yet unknown regulatory mechanisms for PDE5A.
PDE5A appears to jointly influence amygdala volume and emotion recognition performance.
the activation of PDE5 is among the mechanisms contributing to the cGMP decrease, these results suggest that another cGMP phosphodiesterase is also activated by LH signaling.
Report expression of Pde5a1/2/3 in cardiac myocytes and suggest role in induction of cardiac hypertrophy.
Upon S-nitrosylation, PDE5 exhibits reduced activity and degradation via the ubiquitin-proteasome system.
Short-term hemolysis is sufficient to establish a priapism phenotype and results in loss of erectile function. PDE5I treatment ameliorates priapism, in part, because of restored NO balance with decreased ROS (show ROS1 Antibodies) generation and increased PDE5 activity.
Addition of sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, in the drinking water had a small effect in reducing myocyte hypertrophy in wild type mice and no effect in betaRM mice.
findings reveal that excess adenosine-mediated ADORA2B (show ADORA2B Antibodies) signaling underlies reduced penile PDE (show TWIST1 Antibodies) activity by decreasing PDE5 gene expression in a HIF-1alpha (show HIF1A Antibodies)-dependent manner
Findings suggest that continuous, long-term treatment with PDE5 inhibitors reverses eNOS (show NOS3 Antibodies) uncoupling in the sickle cell penis which restores endothelial NO synthesis.
Data indicate that the phosphodiesterase 5 (PDE5) expression is equal in the splenocytes from both genders, but splenocytes from female mice possess higher basal level of cGMP compared to the male ones.
Myocardial PDE5 expression is increased in the hearts of humans and mice with chronic pressure overload.
PDE5 inhibition did not alter atrial natriuretic peptide (show NPPA Antibodies)-stimulated cGMP in the resting heart but augmented it in the transaortic constriction heart.
PDE5 inhibition and increase in cGMP produce pulmonary vasodilation that is mediated in part through inhibition of the ET pathway, thereby precluding an additional vasodilator effect of ETA/ETB (show EDNRB Antibodies) receptor blockade in the presence of PDE5 inhibition.
PDE5 is a key regulator of NO-induced vasodilation in the postnatal pulmonary arteries.
This gene encodes a cGMP-binding, cGMP-specific phosphodiesterase, a member of the cyclic nucleotide phosphodiesterase family. This phosphodiesterase specifically hydrolyzes cGMP to 5'-GMP. It is involved in the regulation of intracellular concentrations of cyclic nucleotides and is important for smooth muscle relaxation in the cardiovascular system. Alternative splicing of this gene results in three transcript variants encoding distinct isoforms.
cGMP-binding cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase
, cGMP-specific 3',5'-cyclic phosphodiesterase
, cGMP-specific phosphodiesterase PDE5A2
, cGMP-specific phosphodiesterase type 5A
, phosphodiesterase isozyme 5
, cGMP-binding cGMP specific phosphodiesterase 5A2
, cGMP-binding cGMP-specific phosphodiesterase
, phosphodiesterase type 5
, cGMP-binding/cGMP-specific phosphodiesterase
, 3',5'-Cyclic GMP Phosphodiesterase
, phosphodiesterase 5A, cGMP-specific
, phosphodiesterase 5a, cGMP-specific
, phosphodiesterase 5a
, cGMP-specific 3',5'-cyclic phosphodiesterase-like
, cyclic nucleotide phosphodiesterase 5a